NCT Number: NCT01148524
Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10
This was a Phase 2b/3, multi-center, extension study of V72P10 to assess antibody persistence at 18 months after the vaccination course in study V72P10 (NCT00661713).
Subjects who participated in study V72P10, and who meet all other enrollment criteria for this extension study, and a group of naïve subjects (defined as subjects who had never received rMenB+OMV NZ or other experimental MenB vaccines) of similar age to the subjects who were eligible to participate in this extension study, performed one study visit in which a single blood sample was drawn for MenB serological analyses.
Looking for future studies?
Notify MeKey information
Conditions
Age range
13 year–19 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2 / Phase 3
Primary location
Centro de Salud Lo Barnechea, Santiago, Chile
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Informed consent was obtained from all the subjects before enrollment into the study after the nature of the study had been explained.
Inclusion criteria
for naive subjects, newly enrolled:
- Healthy adolescents, 13-19 years of age (the age window is defined as the first day the subject turns 13 years of age up to the day before the subject turns 20 years of age).
- For Minor subjects:
- subjects who had given their written assent and whose parent or legal guardians had given written informed consent at the time of enrollment, after the nature of the study had been explained.
For Adult subjects:
- subjects who had given their written informed consent at the time of enrollment, after the nature of the study had been explained.
- Were available for the visit scheduled in the study.
- Were in good health as determined by medical history, physical examination, clinical judgment of the investigator.
Inclusion criteria
for subjects who participated in the V72P10 study (follow-on subjects):
- For Minor subjects: (≤18 years of age)
- subjects who had given their written assent and whose parent or legal guardians had given written informed consent at the time of enrollment, after the nature of the study had been explained.
For Adult subjects: (older than 18 years of age)
- subjects who had given their written informed consent at the time of enrollment, after the nature of the study had been explained.
- Who had participated in the V72P10 study and had received their last vaccination 18 months (-30 + 90 days) before enrollment in V72P10E1.
- Who had completed the vaccination course in study V72P10, according to the protocol.
- Who had provided at least the blood sample one month after the last vaccination in V72P10 (blood sample at visit 6, month 7), according to the protocol.
- Were available for the study visit scheduled in the study.
- Were in good health as determined by medical history, physical examination, clinical judgment of the investigator.
Exclusion criteria
Exclusion criteria
for naïve subjects newly enrolled:
- For Minor subjects:
- subjects who were unwilling or unable to give written informed assent to participate in the study, and whose parent(s)/legal guardian(s) were unwilling or unable to give written informed consent to participate in the study
For Adult subjects:
- subjects who were unwilling or unable to give written informed consent to participate in the study.
- History of any meningococcal B vaccine administration.
- Previous ascertained or suspected disease caused by N. meningitidis.
- Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis.
- Antibiotic treatment within 6 days prior to enrollment.
- Any serious chronic or progressive disease according to the judgment of the investigator (e.g., neoplasm, diabetes mellitus Type I, cardiac disease, hepatic disease, neurological disease or seizure, either associated with fever or as part of an underlying neurological disorder or syndrome, autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition).
- Known or suspected impairment/alteration of the immune system, immunosuppressive therapy, use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids within 30 days prior to enrollment (use of low or moderate doses of inhaled steroids is not an exclusion);
- Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation within 90 days prior to enrollment.
- Participation in another clinical trial within 90 days prior to enrollment or planned for during study.
- Family members and household members of study staff.
- Any condition which, in the opinion of the investigator, could have interfered with the evaluation of the study objectives.
Exclusion criteria
for subjects who participated in the V72P10 study (follow-on subjects):
Exclusion criteria
were the same as for naïve subjects, with the exception of criterion 2.
Treatment and study plan
rMenB+OMV-NZ
BiologicalSubjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
Other names: Serogroup B meningococcal recombinant vaccine
Primary outcomes
-
Percentage of Subjects With hSBA Titers ≥1:4 Against Meningococcal Strains, At 18 Months After Month-6 Vaccination in V72P10 Study, and in Naive Subjects.
Time frame: month 0 (bl=baseline), month 1 and 18 months after last vaccination in V72P10 study.
The immune response was measured as the percentage of subjects with hSBA titers ≥1:4 against meningococcal strains 44/76-SL, 5/99 and NZ98/254, at 18 months after month-6 vaccination of rMenB+OMV-NZ or placebo in V72P10 study, and in age-matched vaccine naive subjects enrolled in this study, evaluated by serum bactericidal assay using human complement (hSBA).
-
Geometric Mean hSBA Titers Directed Against Meningococcal Strains, At 18 Months After Month-6 Vaccination in V72P10 Study, and in Naive Subjects.
Time frame: month 0 (bl=baseline), month 1 and 18 months after last vaccination in V72P10 study.
The immune response was measured as the hSBA geometric mean titers (GMTs) directed against meningococcal strains 44/76-SL, 5/99 and NZ98/254, at 18 months after month-6 vaccination of rMenB+OMV-NZ or placebo in V72P10 study, and in age-matched vaccine naive subjects enrolled in this study.
-
Geometric Mean Ratio at 18 Months After Month-6 Vaccination, Over Baselines at Month 0 and at One Month After the Last rMenB+OMV-NZ Vaccination in the V72P10 Study.
Time frame: month 0 (baseline), month 1 and 18 months after last vaccination in V72P10 study.
The immune response was measured as the geometric mean ratio (GMRs) of hSBA GMTs against meningococcal strains 44/76-SL, 5/99 and NZ98/254 as follow: GMTs at 1 month after last vaccination to baseline GMTs; GMTs at 18 months after last vaccination to baselines GMTs; and GMTs at 18 months after last vaccination to GMTs at 1 month after last vaccination.
-
Geometric Mean Concentration Against Meningococcal 287-953 Antigen, At 18 Months After Month-6 Vaccination in V72P10 Study, and in Naive Subjects.
Time frame: 18 months after last vaccination V72P10 study.
The immune response was measured as the geometric mean concentrations (GMCs) directed against meningococcal 287-953 antigen, evaluated using enzyme-linked immunosorbent assay (ELISA), at 18 months after month-6 vaccination of rMenB+OMV-NZ or placebo in V72P10 study, and in age-matched vaccine naive subjects enrolled in this study.
Sponsors and collaborators
Lead sponsor
Novartis Vaccines
Industry
Registry information
Official study title
A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10.
Important dates
- Study start
- 2010
- Primary completion
- 2012
- Study completion
- 2012
- First posted
- Jun 22, 2010
- Registry last updated
- Jun 15, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
NCT01214837
Bacterial Infections, Bacterial Infections and Mycoses
Birmingham, Alabama, United States
View Trial DetailsSafety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12
NCT00944034
Bacterial Infections, Bacterial Infections and Mycoses
Avenue Albert 1er 185, 5000 Namur, Belgium
View Trial DetailsStudy to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine
NCT01453348
Bacterial Infections, Bacterial Infections and Mycoses
Berlin, Germany
View Trial DetailsEvaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers
NCT01434680
Bacterial Infections, Bacterial Infections and Mycoses
Ul Czerkaska, Bydgoszcz, Poland
View Trial Details